After the release by the manufacturers, Steven Nissen of the Cleveland Clinic, lead investigator in the Light trial, which compared the antiobesity drug Contrave (a combination of naltrexone and bupropion) with placebo in over 8900 overweight subjects, then released data from the trial's halfway mark against the wishes of Contrave's manufacturer, Orexigen Therapeutics. The more complete data seemed to squash hopes of a surprise cardiovascular safety benefit suggested by the first quarter data.
"Patients were misled, investors were misled," Nissen told Forbes, adding that Orexigen had breached the data access agreement signed at the trial's outset.
Contrave, which is marketed in Europe as Mysimba and was approved by the European Union in March, will continue to be sold in the US, but Orexigen must carry out a new postmarket study to assess cardiovascular risk, the Food and Drug Administration has ruled. The requirement has caused a rift between Orexigen and its distribution partner Takeda Pharmaceuticals, which has initiated a formal dispute process and threatened to sever the partnership if Orexigen did not cover the full cost of the new trial, likely to approach $200m (£128m; €180m).
The Light study began when the FDA, concerned that Contrave raised blood pressure, demanded that its maker conduct a large trial to rule out a 40% increase in cardiovascular risk. But rather than wait for this to finish Orexigen was to be allowed to file for approval based on an interim analysis when the trial had recorded a quarter of expected cardiovascular events, if it could demonstrate no doubling of cardiovascular risk.
Orexigen declared in November 2013 that Contrave had easily met this criterion. In fact the first quarter's results showed 41% fewer major cardiovascular events in the treatment group than among those taking placebo, a result so promising that senior executives proved unable to keep it to themselves. A strict data sharing agreement mandated that only a small team within the company, the minimum necessary to file an application, would be able to see the results, which would be kept in locked offices. But Orexigen issued a press release and invited recipients to attend a conference call and webcast on the interim results.
Before long, the FDA later claimed, over 100 unauthorized people had been told the results. On approving Contrave last September, the FDA told Orexigen that the Light study would not be accepted for its regulatory purposes and that another must be conducted.
But the early results had convinced company management that Contrave might find a new market as a cardiovascular treatment, and this March the company made the first quarter's results fully public in a patent application and a securities and exchange filing.
Nissen and his academic collaborators were "livid" when they learned of this from Takeda executives, he told Forbes. A statement from the steering committee said they had "strongly cautioned against any potential misinterpretation of the preliminary 25 percent interim data inappropriately released in this disclosure by Orexigen." The case "clearly illustrates the risks inherent in prejudgement of clinical trial results," the statement added.
Orexigen's shares have fallen 30% since the less promising midpoint data were released. In a statement the company said that it agreed with the halting of the trial but not with the release of the midpoint data. Nissen told Forbes that the trial was actually halted soon after the patent filing in March, but the academic investigators had been unable to agree on a press release with Orexigen for six weeks, because the company was unwilling to release the midpoint data. 
